RESUMEN
The trithorax genes encode an evolutionarily conserved family of proteins that function to maintain specific patterns of gene expression throughout cellular development. Members of this protein family contain a highly conserved 130- to 140-amino acid motif termed the SET domain. We report the purification and molecular identification of the subunits of a protein complex in the yeast Saccharomyces cerevisiae that includes the trithorax-related protein Set1. This protein complex, which we have named COMPASS (Complex Proteins Associated with Set1), consists of seven polypeptides ranging from 130 to 25 kDa. The same seven proteins were identified in COMPASS purified either by conventional biochemical chromatography or tandem-affinity tagging of the individual subunits of the complex. Null mutants missing any one of the six nonessential subunits of COMPASS grow more slowly than wild-type cells under normal conditions and demonstrate growth sensitivity to hydroxyurea. Furthermore, gene expression profiles of strains missing either of two nonessential subunits of COMPASS are altered in similar ways, suggesting these proteins have similar roles in gene expression in vivo. Molecular characterization of trithorax complexes will facilitate defining the role of this class of proteins in the regulation of gene expression and how their misregulation results in the development of human cancer.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Factores de Transcripción/metabolismo , Cromatografía Liquida , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/aislamiento & purificación , Electroforesis en Gel de Poliacrilamida , Regulación de la Expresión Génica , Silenciador del Gen , N-Metiltransferasa de Histona-Lisina , Hidroxiurea/farmacología , Mutación , Fenotipo , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/aislamiento & purificación , Telómero , Factores de Transcripción/genética , Factores de Transcripción/aislamiento & purificaciónRESUMEN
Several factors have been biochemically characterized based on their ability to increase the overall rate of transcription elongation catalyzed by the multiprotein complex RNA polymerase II (Pol II). Among these, the ELL family of elongation factors has been shown to increase the catalytic rate of transcription elongation in vitro by suppressing transient pausing. Several fundamental biological aspects of this class of elongation factors are not known. We have cloned the Drosophila homolog (dELL) in order to test whether ELL family proteins are actually associated with the elongating Pol II in vivo. Here we report that dELL is a nuclear protein, which, like its mammalian homologs, can increase the catalytic rate of transcription elongation by Pol II in vitro. Interestingly, we find that dELL co-localizes extensively with the phosphorylated, actively elongating form of Pol II at transcriptionally active sites on Drosophila polytene chromosomes. Furthermore, dELL is relocalized from a widespread distribution pattern on polytenes under normal conditions to very few transcriptionally active puff sites upon heat shock. This observation indicates a dynamic pattern of localization of dELL in cells, which is a predicted characteristic of a Pol II general elongation factor. We also demonstrate that dELL physically interacts with Pol II. Our results strongly suggest that dELL functions with elongating RNA polymerase II in vivo.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas de Neoplasias , Factores de Elongación de Péptidos/metabolismo , ARN Polimerasa II/metabolismo , Factores de Transcripción/metabolismo , Transcripción Genética/fisiología , Animales , Núcleo Celular/metabolismo , Núcleo Celular/ultraestructura , Cromosomas/metabolismo , Cromosomas/ultraestructura , Clonación Molecular , Proteínas de Unión al ADN/genética , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Drosophila melanogaster , Embrión no Mamífero/citología , Embrión no Mamífero/metabolismo , Regulación del Desarrollo de la Expresión Génica , Proteínas de Choque Térmico/genética , Respuesta al Choque Térmico/fisiología , Inmunohistoquímica , Sustancias Macromoleculares , Datos de Secuencia Molecular , Complejos Multiproteicos , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Factores de Elongación de Péptidos/genética , Unión Proteica/fisiología , Análisis de Secuencia de ADN , Homología de Secuencia de Aminoácido , Factores de Transcripción/genética , Factores de Elongación TranscripcionalRESUMEN
The heterodimeric Elongin BC complex has been shown to interact in vitro and in mammalian cells with a conserved BC-box motif found in a growing number of proteins including RNA polymerase II elongation factor Elongin A, SOCS-box proteins, and the von Hippel-Lindau (VHL) tumor suppressor protein. Recently, the VHL-Elongin BC complex was found to interact with a module composed of Cullin family member Cul2 and RING-H2 finger protein Rbx1 to reconstitute a novel E3 ubiquitin ligase that activates ubiquitylation by the E2 ubiquitin-conjugating enzymes Ubc5 and Cdc34. In the context of the VHL ubiquitin ligase, Elongin BC functions as an adaptor that links the VHL protein to the Cul2/Rbx1 module, raising the possibility that the Elongin BC complex could function as an integral component of a larger family of E3 ubiquitin ligases by linking alternative BC-box proteins to Cullin/Rbx1 modules. In this report, we describe identification and purification from rat liver of a novel leucine-rich repeat-containing BC-box protein, MUF1, which we demonstrate is capable of assembling with a Cullin/Rbx1 module containing the Cullin family member Cul5 to reconstitute ubiquitin ligase activity. In addition, we show that the additional BC-box proteins Elongin A, SOCS1, and WSB1 are also capable of assembling with the Cul5/Rbx1 module to reconstitute potential ubiquitin ligases. Taken together, our findings identify MUF1 as a new member of the BC-box family of proteins, and they predict the existence of a larger family of Elongin BC-based E3 ubiquitin ligases.
Asunto(s)
Proteínas Portadoras/química , Proteínas Portadoras/metabolismo , Leucina/química , Factores de Transcripción/química , Complejos de Ubiquitina-Proteína Ligasa , Secuencia de Aminoácidos , Ciclosoma-Complejo Promotor de la Anafase , Animales , Proteínas Portadoras/aislamiento & purificación , Línea Celular , Clonación Molecular , ADN Complementario/metabolismo , Elonguina , Insectos , Ligasas/metabolismo , Masculino , Proteínas de la Membrana/metabolismo , Datos de Secuencia Molecular , Unión Proteica , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/metabolismo , Secuencias Repetitivas de Aminoácido , Homología de Secuencia de Aminoácido , Factores de Transcripción/metabolismo , Enzimas Ubiquitina-Conjugadoras , Ubiquitina-Proteína Ligasas , Ubiquitinas/metabolismoRESUMEN
TFIIF, ELL, and Elongin belong to a class of RNA polymerase II transcription factors that function similarly to activate the rate of elongation by suppressing transient pausing by polymerase at many sites along DNA templates. SII is a functionally distinct RNA polymerase II elongation factor that promotes elongation by reactivating arrested polymerase. Studies of the mechanism of SII action have shown (i) that arrest of RNA polymerase II results from irreversible displacement of the 3'-end of the nascent transcript from the polymerase catalytic site and (ii) that SII reactivates arrested polymerase by inducing endonucleolytic cleavage of the nascent transcript by the polymerase catalytic site thereby creating a new transcript 3'-end that is properly aligned with the catalytic site and can be extended. SII also induces nascent transcript cleavage by paused but non-arrested RNA polymerase II elongation intermediates, leading to the proposal that pausing may result from reversible displacement of the 3'-end of nascent transcripts from the polymerase catalytic site. On the basis of evidence consistent with the model that TFIIF, ELL, and Elongin suppress pausing by preventing displacement of the 3'-end of the nascent transcript from the polymerase catalytic site, we investigated the possibility of cross-talk between SII and transcription factors TFIIF, ELL, and Elongin. These studies led to the discovery that TFIIF, ELL, and Elongin are all capable of inhibiting SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates. Here we present these findings, which bring to light a novel activity associated with TFIIF, ELL, and Elongin and suggest that these transcription factors may expedite elongation not only by increasing the forward rate of nucleotide addition by RNA polymerase II, but also by inhibiting SII-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates.
Asunto(s)
Proteínas de Unión al ADN/fisiología , Proteínas de Neoplasias , Factores de Elongación de Péptidos , ARN Mensajero/metabolismo , Factores Generales de Transcripción , Factores de Transcripción TFII , Factores de Transcripción/metabolismo , Factores de Transcripción/fisiología , Factores de Elongación Transcripcional , Secuencia de Bases , ADN , Elonguina , Humanos , Hidrólisis , Regiones Promotoras Genéticas , Proteínas Recombinantes/metabolismoRESUMEN
The ELL gene encodes an RNA polymerase II transcription factor that frequently undergoes translocation with the MLL gene in acute human myeloid leukemia. Here, we report that ELL can regulate cell proliferation and survival. In order to better understand the physiological role of the ELL protein, we have developed an ELL-inducible cell line. Cells expressing ELL were uniformly inhibited for growth by a loss of the G(1) population and an increase in the G(2)/M population. This decrease in cell growth is followed by the condensation of chromosomal DNA, activation of caspase 3, poly(ADP ribose) polymerase cleavage, and an increase in sub-G(1) population, which are all indicators of the process of programmed cell death. In support of the role of ELL in induction of cell death, expression of an ELL antisense RNA or addition of the caspase inhibitor ZVAD-fmk results in a reversal of ELL-mediated death. We have also demonstrated that the C-terminal domain of ELL, which is conserved among the ELL family of proteins that we have cloned (ELL, ELL2, and ELL3), is required for ELL's activity in the regulation of cell growth. These novel results indicate that ELL can regulate cell growth and survival and may explain how ELL translocations result in the development of human malignancies.
Asunto(s)
Proteínas de Unión al ADN/fisiología , Leucemia Mieloide Aguda/metabolismo , Proteínas de Neoplasias , Factores de Elongación de Péptidos , Factores de Transcripción/fisiología , Clorometilcetonas de Aminoácidos/farmacología , Antígenos de Diferenciación , Apoptosis , Western Blotting , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Proteínas de Ciclo Celular , Muerte Celular , División Celular , Línea Celular , Supervivencia Celular , Inhibidores de Cisteína Proteinasa/farmacología , ADN/metabolismo , Proteínas de Unión al ADN/genética , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Citometría de Flujo , Fase G1 , Fase G2 , Humanos , Leucemia Mieloide Aguda/genética , Microscopía Fluorescente , Microscopía de Contraste de Fase , Mitosis , Oligonucleótidos Antisentido/metabolismo , Plásmidos/metabolismo , Poli(ADP-Ribosa) Polimerasas/metabolismo , Propidio/farmacología , Proteína Fosfatasa 1 , Proteínas/metabolismo , ARN Mensajero/metabolismo , Factores de Tiempo , Factores de Transcripción/genética , Factores de Elongación Transcripcional , Transfección , Translocación Genética , Células Tumorales CultivadasRESUMEN
RNA polymerase II elongation factor ELL was recently purified from rat liver as a component of a multiprotein complex containing ELL and three ELL-associated proteins (EAPs) of approximately 45 (EAP45), approximately 30 (EAP30), and approximately 20 (EAP20) kDa (Shilatifard, A. (1998) J. Biol. Chem. 273, 11212-11217). Cloning of cDNA encoding the EAP30 protein revealed that it shares significant sequence similarity with the product of the Saccharomyces cerevisiae SNF8 gene (Schmidt, A. E., Miller, T., Schmidt, S. L., Shiekhattar, R., and Shilatifard, A. (1999) J. Biol. Chem. 274, 21981-21985), which is required for efficient derepression of glucose-repressed genes. Here we report the cloning of cDNAs encoding the EAP45 and EAP20 proteins. In addition, we identify the S. cerevisiae VPS36 and YJR102c genes as potential orthologs of EAP45 and EAP20 and show that they are previously uncharacterized SNF genes with properties very similar to SNF8.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Regulación Fúngica de la Expresión Génica/fisiología , Glucosa/farmacología , Proteínas de Neoplasias , Factores de Elongación de Péptidos , Saccharomyces cerevisiae/genética , Factores de Transcripción/metabolismo , Secuencia de Aminoácidos , Animales , Caenorhabditis elegans/genética , Clonación Molecular , Secuencia Conservada , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/genética , Drosophila melanogaster/genética , Complejos de Clasificación Endosomal Requeridos para el Transporte , Proteínas Fúngicas/química , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Regulación Fúngica de la Expresión Génica/efectos de los fármacos , Humanos , Hígado/enzimología , Mamíferos , Ratones , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Subunidades de Proteína , ARN Polimerasa II/metabolismo , Ratas , Proteínas Recombinantes/metabolismo , Saccharomyces cerevisiae/efectos de los fármacos , Saccharomyces cerevisiae/metabolismo , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Factores de Transcripción/química , Factores de Transcripción/genética , Factores de Elongación TranscripcionalRESUMEN
The t(11;19)(q23;p13.1) chromosomal translocation in acute myeloid leukemias fuses the gene encoding transcriptional elongation factor ELL to the MLL gene with consequent expression of an MLL-ELL chimeric protein. To identify potential mechanisms of leukemogenesis by MLL-ELL, its transcriptional and oncogenic properties were investigated. Fusion with MLL preserves the transcriptional elongation activity of ELL but relocalizes it from a diffuse nuclear distribution to the nuclear bodies characteristic of MLL. Using a serial replating assay, it was demonstrated that the MLL-ELL chimeric protein is capable of immortalizing clonogenic myeloid progenitors in vitro after its retroviral transduction into primary murine hematopoietic cells. However, a structure-function analysis indicates that the elongation domain is not essential for myeloid transformation because mutants lacking elongation activity retain a potent ability to immortalize myeloid progenitors. Rather, the highly conserved carboxyl terminal R4 domain is both a necessary and a sufficient contribution from ELL for the immortalizing activity associated with MLL-ELL. The R4 domain demonstrates potent transcriptional activation properties and is required for transactivation of a HoxA7 promoter by MLL-ELL in a transient transcriptional assay. These data indicate that neoplastic transformation by the MLL-ELL fusion protein is likely to result from aberrant transcriptional activation of MLL target genes. Thus, in spite of the extensive diversity of MLL fusion partners, these data, in conjunction with previous studies of MLL-ENL, suggest that conversion of MLL to a constitutive transcriptional activator may be a general model for its oncogenic conversion in myeloid leukemias. (Blood. 2000;96:3887-3893)
Asunto(s)
Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/farmacología , Leucemia Mieloide/etiología , Células Progenitoras Mieloides/efectos de los fármacos , Proteínas de Neoplasias , Factores de Elongación de Péptidos/farmacología , Proto-Oncogenes , Factores de Transcripción/farmacología , Enfermedad Aguda , Secuencia de Aminoácidos , Animales , Células de la Médula Ósea , Núcleo Celular/química , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Proteínas de Unión al ADN/química , Embrión de Mamíferos/citología , Fibroblastos/citología , N-Metiltransferasa de Histona-Lisina , Interleucina-3/farmacología , Leucemia Mieloide/metabolismo , Leucemia Mieloide/patología , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Células Progenitoras Mieloides/química , Células Progenitoras Mieloides/citología , Proteína de la Leucemia Mieloide-Linfoide , Proteínas de Fusión Oncogénica/genética , Proteínas de Fusión Oncogénica/farmacología , Factores de Elongación de Péptidos/genética , Estructura Terciaria de Proteína , ARN Polimerasa II/metabolismo , Relación Estructura-Actividad , Factores de Transcripción/química , Factores de Transcripción/genética , Transcripción Genética/efectos de los fármacos , Factores de Elongación Transcripcional , Transfección , Translocación GenéticaRESUMEN
The elongation stage of eukaryotic mRNA synthesis can be regulated by transcription factors that interact directly with the RNA polymerase II (pol II) elongation complex and by activities that modulate the structure of its chromatin template. Recent studies have revealed new elongation factors and have implicated the general initiation factors TFIIE, TFIIF and TFIIH, as well as the C-terminal domain (CTD) of the largest subunit of pol II, in elongation. The recently reported high-resolution crystal structure of RNA polymerase II, which provides insight into the architecture of the elongation complex, marks a new era of investigation into transcription elongation.
Asunto(s)
ARN Polimerasa II/química , ARN Polimerasa II/metabolismo , ARN Mensajero/biosíntesis , Cromatina/metabolismo , Regulación de la Expresión Génica , Modelos Biológicos , ARN Polimerasa II/genética , Factores de Transcripción/química , Factores de Transcripción/metabolismoRESUMEN
The human ELL gene, which is a frequent target for translocation in acute myeloid leukemia, was initially isolated from rat liver nuclei and found to be an RNA polymerase II elongation factor. Based on homology to ELL, we later cloned ELL2 and demonstrated that it can also increase the catalytic rate of transcription elongation by RNA polymerase II. To better understand the role of ELL proteins in the regulation of transcription by RNA polymerase II, we have initiated a search for proteins related to ELLs. In this report, we describe the molecular cloning, expression, and characterization of ELL3, a novel RNA polymerase II elongation factor approximately 50% similar to both ELL and ELL2. Our transcriptional studies have demonstrated that ELL3 can also increase the catalytic rate of transcription elongation by RNA polymerase II. The C-terminal domain of ELL, which we recently demonstrated to be required and sufficient for the immortalization of myeloid progenitor cells, shares strong similarities to the C-terminal domain of ELL3. ELL3 was localized by immunofluorescence to the nucleus of cells, and Northern analysis indicated that ELL3 is a testis-specific RNA polymerase II elongation factor.
Asunto(s)
ARN Polimerasa II/metabolismo , Testículo/química , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Transcripción Genética , Secuencia de Aminoácidos , Catálisis , Clonación Molecular , Técnica del Anticuerpo Fluorescente , Perfilación de la Expresión Génica , Humanos , Cinética , Masculino , Datos de Secuencia Molecular , Células Progenitoras Mieloides , Proteínas Nucleares/química , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Especificidad de Órganos , ARN Mensajero/análisis , ARN Mensajero/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Testículo/enzimología , Testículo/metabolismo , Factores de Transcripción/química , Factores de Transcripción/aislamiento & purificación , Factores de Elongación TranscripcionalRESUMEN
Several lines of evidence suggest that the mixed lineage leukemia protein (MLL, ALL-1, HRX) plays a role in regulating myelomonocytic differentiation. In this study we examined the effect of expression of MLL-AF9 on differentiation of the monoblastic U937 cell line by using a tetracycline-inducible expression system. MLL-AF9 arrested growth of U937 cells and induced these cells to differentiate into macrophages; induction was accompanied by expression of CD11b and CD14 and ultimately cell death. Deletion mutants of MLL-AF9 were used to map the sequences responsible for this effect. The amino-terminal half of MLL was sufficient for both cell cycle arrest and macrophage differentiation, whereas the carboxyl terminus of MLL or AF9 was found to be dispensable for this effect. Further deletions showed that a 35-kDa amino-terminal fragment spanning two AT hook motifs was sufficient for cell cycle arrest, up-regulation of p21(Cip1) and p27(Kip1), and partial differentiation toward macrophages. These findings suggest a possible role for the MLL AT hook-containing region in regulating myelomonocytic differentiation.
Asunto(s)
Técnicas de Cultivo de Célula/métodos , Ciclo Celular/fisiología , Proteínas de Unión al ADN/fisiología , Monocitos/fisiología , Proto-Oncogenes , Factores de Transcripción , Western Blotting , Muerte Celular , Diferenciación Celular/fisiología , Proteínas de Unión al ADN/química , Citometría de Flujo , Eliminación de Gen , N-Metiltransferasa de Histona-Lisina , Humanos , Macrófagos/citología , Macrófagos/fisiología , Monocitos/citología , Mutagénesis , Proteína de la Leucemia Mieloide-Linfoide , Plásmidos , Estructura Terciaria de Proteína , Factores de Tiempo , Células U937RESUMEN
The activity of cyclin-dependent protein kinases (cdks) is physiologically regulated by phosphorylation, association with the specific cyclin subunits, and repression by specific cdk inhibitors. All three physiological regulatory mechanisms are specific for one or more cdks, but none is known to be substrate specific. In contrast, synthetic cdk peptide inhibitors that specifically inhibit cdk phosphorylation of only some substrates, "aptamers," have been described. Here, we show that PC4, a naturally occurring transcriptional coactivator, competitively inhibits cdk-1, -2, and -7-mediated phosphorylation of the largest subunit of RNA polymerase II (RNAPII), but it does not inhibit phosphorylation of other substrates of the same kinases. Interestingly, the phosphorylated form of PC4 is devoid of kinase inhibitory activity. We also show that wild-type PC4 but not the kinase inhibitory-deficient mutant of PC4 represses transcription in vivo. Our results point to a novel role for PC4 as a specific inhibitor of RNAPII phosphorylation.
Asunto(s)
ARN Polimerasa II/metabolismo , Proteínas Represoras/farmacología , Transactivadores/farmacología , Línea Celular , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Humanos , Proteínas Inmediatas-Precoces , Cinética , Proteínas de la Membrana , Mutación , Fosforilación/efectos de los fármacos , Proteínas Recombinantes/farmacología , Proteínas Represoras/genética , Especificidad por Sustrato , Transactivadores/genética , Transcripción Genética/efectos de los fármacos , TransfecciónRESUMEN
The product of the human oncogene ELL encodes an RNA polymerase II transcription factor that undergoes frequent translocation in acute myeloid leukemia (AML). In addition to its elongation activity, ELL contains a novel type of RNA polymerase II interaction domain that is capable of repressing polymerase activity in promoter-specific transcription. Remarkably, the ELL translocation that is found in patients with AML results in the deletion of exactly this functional domain. Here we report that the EAP30 subunit of the ELL complex has sequence homology to the Saccharomyces cerevisiae SNF8, whose genetic analysis suggests its involvement in the derepression of gene expression. Remarkably, EAP30 can interact with ELL and derepress ELL's inhibitory activity in vitro. This finding may reveal a key role for EAP30 in the pathogenesis of human leukemia.
Asunto(s)
Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Proteínas de Neoplasias , Factores de Elongación de Péptidos , Regiones Promotoras Genéticas , ARN Polimerasa II/metabolismo , Proteínas de Saccharomyces cerevisiae , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Transcripción Genética , Secuencia de Aminoácidos , Secuencia de Bases , Clonación Molecular , Proteínas de Unión al ADN/química , Complejos de Clasificación Endosomal Requeridos para el Transporte , Represión Enzimática , Proteínas Fúngicas/química , Humanos , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/metabolismo , Sustancias Macromoleculares , Datos de Secuencia Molecular , Oncogenes , ARN Polimerasa II/biosíntesis , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Saccharomyces cerevisiae/genética , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Factores de Transcripción/química , Factores de Elongación TranscripcionalRESUMEN
Cyclin-dependent kinase 7 (CDK7) can be isolated as a subunit of a trimeric kinase complex functional in activation of the mitotic promoting factor. In this study, we demonstrate that the trimeric cdk-activating kinase (CAK) acts as a transcriptional repressor of class II promoters and show that repression results from CAK impeding the entry of RNA polymerase II and basal transcription factor IIF into a competent preinitiation complex. This repression is independent of CDK7 kinase activity. We find that the p36/MAT1 subunit of CAK is required for transcriptional repression and the repression is independent of the promoter used. Our results demonstrate a central role for CAK in regulation of messenger RNA synthesis by either inhibition of RNA polymerase II-catalyzed transcription or stimulation of transcription through association with basal transcription repair factor IIH.
Asunto(s)
Quinasas Ciclina-Dependientes , Proteínas Serina-Treonina Quinasas/fisiología , Proteínas Represoras/fisiología , Factores de Transcripción TFII , Transcripción Genética/fisiología , Biopolímeros , Células HeLa , Humanos , Proteínas Serina-Treonina Quinasas/química , ARN Polimerasa II/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Proteínas Represoras/química , Factores de Transcripción/metabolismo , Quinasa Activadora de Quinasas Ciclina-DependientesRESUMEN
Mammalian Elongin B is a 118-amino acid protein composed of an 84-amino acid amino-terminal ubiquitin-like domain and a 34-amino acid carboxyl-terminal tail. Elongin B is found in cells as a subunit of the heterodimeric Elongin BC complex, which was originally identified as a positive regulator of RNA polymerase II elongation factor Elongin A and subsequently as a component of the multiprotein von Hippel-Lindau tumor suppressor and suppressor of cytokine signaling complexes. As part of our effort to understand how the Elongin BC complex regulates the activity of Elongin A, we are characterizing Elongin B functional domains. In this report, we show that the Elongin B ubiquitin-like domain is necessary and sufficient for interaction with Elongin C and for positive regulation of Elongin A transcriptional activity. In addition, by site-directed mutagenesis of the Elongin B ubiquitin-like domain, we identify a short Elongin B region that is important for its interaction with Elongin C. Finally, we observe that both the ubiquitin-like domain and carboxyl-terminal tail are conserved in Drosophila melanogaster and Caenorhabditis elegans Elongin B homologs that efficiently substitute for mammalian Elongin B in reconstitution of the transcriptionally active Elongin ABC complex, suggesting that the carboxyl-terminal tail performs an additional function not detected in our assays.
Asunto(s)
Factores de Transcripción/química , Ubiquitinas/química , Secuencia de Aminoácidos , Animales , Sitios de Unión , Evolución Biológica , Caenorhabditis elegans/química , Proteínas de Caenorhabditis elegans , Secuencia Conservada , Drosophila melanogaster/química , Elonguina , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Homología de Secuencia de Aminoácido , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
The synthesis of mature and functional messenger RNA by eukaryotic RNA polymerase II (Pol II) is a complex, multistage process requiring the cooperative action of many cellular proteins. This process, referred to collectively as the transcription cycle, proceeds via five stages: preinitiation, initiation, promoter clearance, elongation, and termination. During the past few years, fundamental studies of the elongation stage of transcription have demonstrated the existence of several families of Pol II elongation factors governing the activity of Pol II. It is now clear that the elongation stage of transcription is a critical stage for the regulation of gene expression. In fact, two of these elongation factors, ELL and elongin, have been implicated in human cancer. This article will review the proteins involved in the regulation of the elongation stage of transcription by Pol II, describing the recent experimental findings that have propelled vigorous research on the properties and function of the elongating RNA polymerase II. --Shilatifard, A. Factors regulating the transcriptional elongation activity of RNA polymerase II.
Asunto(s)
Ligasas , ARN Polimerasa II/metabolismo , Transcripción Genética , Proteínas Supresoras de Tumor , Ubiquitina-Proteína Ligasas , Secuencia de Aminoácidos , Animales , Genes Supresores de Tumor , Humanos , Datos de Secuencia Molecular , Nucleosomas/metabolismo , Factores de Elongación de Péptidos/metabolismo , Procesamiento Proteico-Postraduccional , Proteínas/genética , Homología de Secuencia de Aminoácido , Proteína Supresora de Tumores del Síndrome de Von Hippel-LindauRESUMEN
The human ELL gene on chromosome 19 undergoes frequent translocation with the trithorax-like MLL gene on chromosome 11 in acute myeloid leukemia. Recently, it was demonstrated that the product of the human ELL gene encodes an RNA polymerase II elongation factor (Shilatifard, A., Lane, W. S., Jackson, K. W., Conaway, R. C., and Conaway, J. W. (1996) Science 271, 1873-1876). In addition to its elongation regulatory activity, ELL contains a novel type of RNA polymerase II interaction domain that is capable of negatively regulating polymerase activity in promoter-specific transcription in vitro (Shilatifard, A., Haque, D., Conaway, R. C., and Conaway, J. W. (1997) J. Biol. Chem. 272, 22355-22363). Here, we report the identification and purification of a large ELL-containing complex that contains three proteins in addition to ELL and that we have named the Holo-ELL complex. The Holo-ELL complex can increase the catalytic rate of transcription elongation by RNA polymerase II. However, unlike the ELL polypeptide alone, the Holo-ELL complex is not capable of negatively regulating polymerase activity in promoter-specific transcription in vitro. The inability of the Holo-ELL complex to negatively regulate polymerase activity in promoter-specific transcription suggests that one or more of the ELL-associated proteins regulate this activity, possibly through an interaction with the N-terminal domain of the ELL protein, which was shown to be required for the transcriptional inhibitory activity of ELL. Characterization of these ELL interacting proteins should help define the regulation of the biochemical activities of ELL and how loss of this regulation leads to the development of acute myeloid leukemia.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas de Neoplasias/metabolismo , Factores de Elongación de Péptidos/metabolismo , Factores de Transcripción/metabolismo , Animales , Cromatografía DEAE-Celulosa , Cromatografía en Gel , Proteínas de Unión al ADN/aislamiento & purificación , Humanos , Cinética , Hígado/metabolismo , Proteínas de Neoplasias/aislamiento & purificación , Factores de Elongación de Péptidos/aislamiento & purificación , ARN Polimerasa II/metabolismo , Ratas , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Factores de Transcripción/aislamiento & purificación , Factores de Elongación TranscripcionalRESUMEN
Eukaryotic messenger RNA (mRNA) synthesis is a complex multi-stage process that requires the concerted action of many cellular factors to generate a mature functional message. This elaborate process by RNA polymerase II (pol II) proceeds via multiple stages-preinitiation, initiation (Figure 1), promoter clearance, elongation (Figure 1) and termination - which have come to be referred to collectively as the transcription cycle. Although the preinitiation and initiation stages of transcription have received the most attention during the past decade, the past few years have been a watershed for biochemical studies of the pol II elongation complex. Recent studies have demonstrated the existence of several families of pol II elongation factors and nuclear proteins that can govern the activity of pol II during mRNA chain elongation. New findings have revealed that the elongation stage of transcription is a critical site for the regulation of gene expression. Evidence obtained to date suggests that eukaryotes regulate elongation by both 'general' and 'activator dependent' mechanisms. These mechanisms necessitate alteration of pol II's catalytic site, modification of chromatin structure, phosphorylation of the pol II carboxyl-terminal domain (CTD) and involvement of other components of the transcription machinery to increase the rate and efficiency of transcription elongation. This minireview is an annotation on the recent progress in studies of the biochemical mechanism and molecular regulation of the elongation stages of eukaryotic mRNA synthesis. The recent developments that have guided our understanding and propelled current research on transcription elongation by mammalian pol II will be described here.
Asunto(s)
ARN Polimerasa II/química , Células Eucariotas/fisiología , Regulación de la Expresión Génica/genética , Neoplasias/genética , Regiones Promotoras Genéticas/genética , ARN Mensajero/biosíntesis , Factores de Transcripción/química , Factores de Transcripción/fisiología , Transcripción Genética/genéticaRESUMEN
The human ELL gene on chromosome 19p13.1 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11q23 in acute myeloid leukemia. Recently, the human ELL gene was shown to encode an RNA polymerase II elongation factor that activates elongation by suppressing transient pausing by polymerase at many sites along the DNA. In this report, we identify and characterize two overlapping ELL functional domains that govern its interaction with RNA polymerase II and the ternary elongation complex. Our findings reveal that, in addition to its elongation activation domain, ELL contains a novel type of RNA polymerase II interaction domain that is capable of negatively regulating polymerase activity in promoter-specific transcription initiation in vitro. Notably, the MLL-ELL translocation results in deletion of a portion of this functional domain, and ELL mutants lacking sequences deleted by the translocation bind RNA polymerase II and are fully active in elongation, but fail to inhibit initiation. Taken together, these results raise the possibility that the MLL-ELL translocation could alter ELL-RNA polymerase II interactions that are not involved in regulation of elongation.
Asunto(s)
Cromosomas Humanos Par 19 , Proteínas de Unión al ADN/metabolismo , Proteínas de Neoplasias/metabolismo , Extensión de la Cadena Peptídica de Translación , Factores de Elongación de Péptidos , Proto-Oncogenes , ARN Polimerasa II/metabolismo , Factores de Transcripción/metabolismo , Activación Enzimática , N-Metiltransferasa de Histona-Lisina , Humanos , Proteína de la Leucemia Mieloide-Linfoide , Regiones Promotoras Genéticas , Factor de Transcripción TFIIB , Factor de Transcripción TFIID , Factores de Transcripción TFII/metabolismo , Transcripción Genética , Factores de Elongación Transcripcional , Dedos de ZincRESUMEN
Over the past year, key advances in several areas of research on the structure and function of the RNA polymerase (pol II) elongation complex have shed considerable light on the mechanisms governing the elongation stage of eukaryotic mRNA synthesis. Novel features of the regulation of elongation by DNA and RNA binding transcriptional activators have been brought to light; the mechanisms of action of elongation factors that suppress pausing and premature arrest by transcribing pol II have been defined in greater detail; and novel elongation factors implicated in human disease have been identified and characterized.
Asunto(s)
Extensión de la Cadena Peptídica de Translación , ARN Polimerasa II/metabolismo , Transcripción Genética , Animales , Humanos , Factores de Elongación de Péptidos/metabolismo , Transactivadores/metabolismoRESUMEN
We recently isolated an RNA polymerase II elongation factor from rat liver nuclei and found it to be homologous to the product of the human ELL gene, a frequent target for translocations in acute myeloid leukemia. To further our understanding of the possible role(s) of ELL in transcriptional regulation and human disease, we initiated a search for ELL-related proteins. In this report we describe molecular cloning, expression, and characterization of human ELL2, a novel RNA polymerase II elongation factor 49% identical and 66% similar to ELL. Mechanistic studies indicate that ELL2 and ELL possess similar transcriptional activities. Structure-function studies localize the ELL2 elongation activation domain to an ELL2 N-terminal region that is highly homologous to ELL. Finally, Northern blot analysis reveals that the ELL2 and ELL genes are transcribed in many of the same tissues, but that the ratio of their transcripts exhibits tissue-to-tissue variation, raising the possibility that ELL2 and ELL may not perform completely general functions, but, instead, may perform gene- or tissue-specific functions.